Severe symptomatic dose-limiting hypophosphatemia hepatic arterial infusion recombinant tumor necrosis factor patients liver metastases Twenty-two patients liver metastases courses recombinant tumor necrosis factor rTNF hepatic arterial infusion doses days continuous infusion induction significant dose-related severe albeit transient hypophosphatemia mg/dl significant right-sided myocardial dysfunction severe lassitude side effects rTNF intravenous phosphate supplementation significant consistent increase urinary phosphate excretion rTNF-induced hypophosphatemia intracellular shift phosphate tumor regression levels serum phosphate hypophosphatemia important antitumor effects rTNF 